Get the Daily Brief
Latest Biotech News
mTORC1 in ILC2s... Links neurons to allergic lung inflammation
Wang, Hu, Chen and colleagues published in Nature Communications that mTORC1 signaling within group 2 innate lymphoid cells (ILC2s) mediates neuro-immune cross-talk driving allergic lung...
Complement genes: alter pancreatic cancer susceptibility and outcomes
A Nature Communications analysis dissected germline and somatic variation in complement system genes and linked them to pancreatic cancer risk, tumor microenvironment changes, and patient...
Ultrasound-triggered PANoptosis: piezoelectric nanocatalysts induce tumor death
Xu et al. reported an ultrasound-activated therapy using piezoelectric nanocatalysts that triggers PANoptosis—a combined inflammatory cell-death program—in tumor models. The approach uses focused...
FDA biosimilar plan: patent office rules threaten rollout
The FDA announced a proposal to regulate biosimilars more like small-molecule generics, aiming to halve development time and lower costs substantially. Industry leaders including Stefan Glombitza...
CRISPR test detects BK and JC viruses after kidney transplant
Researchers led by Liu, Y., Xu JS., and Cao L. developed a CRISPR-based assay to detect BK and JC polyomaviruses in kidney-transplant recipients. The team validated the assay’s specificity and...
Sibiriline: single compound blocks necroptosis and ferroptosis
Scientists reported discovery of Sibiriline, a small-molecule inhibitor that simultaneously blocks necroptosis and ferroptosis—two regulated cell‑death pathways implicated in degenerative and...
Anti‑PD‑1 plus chemotherapy rewires early hormone‑positive breast tumors
A new clinical-translational study found that combining anti‑PD‑1 immunotherapy with chemotherapy induces profound cellular reprogramming in early-stage, hormone-receptor–positive (HR+) breast...
Complement‑system genes linked to pancreatic cancer risk and outcomes
A Nature Communications study mapped genetic variation across complement cascade genes and found associations with pancreatic cancer susceptibility and prognosis. The multi-omic analysis...
Beyond BRCA: genomic evolution mapped in high‑grade serous ovarian cancer
A genomic study led by Pokorna, Orlickova, Machackova and colleagues reconstructed evolutionary trajectories in high‑grade serous ovarian cancer (HGSOC) beyond canonical BRCA alterations. By...
Human genetics tie gut microbiota to bone mass
A Nature Communications study combined human genetic data and microbiome profiling to demonstrate a causal link between gut microbial composition and bone mass regulation. Using genome-wide...
Genome graphs reveal structural variation driving TB evolution
Researchers applied genome-graph methods to Mycobacterium tuberculosis and uncovered large structural variants that traditional reference-based analyses miss. The Nature Communications paper shows...
Ultrasound plus piezoelectric nanocatalysts induces tumor PANoptosis
Xu and colleagues published a preclinical report in Military Medicine Research describing a tumor-catalytic PANoptosis approach: ultrasound-activated piezoelectric nanocatalysts trigger...
Plasma LPS levels forecast mortality among acutely ill children
A multicenter study in low‑ and middle‑income countries identified plasma lipopolysaccharide (LPS) concentration as a strong predictor of mortality in acutely ill children. Researchers measured...
mRNA retools allogeneic stem cells: DC‑25 emerges
Researchers report an mRNA-based engineering approach that upgrades mesenchymal stem cells (MSCs) to create an off-the-shelf allogeneic immunotherapy called DC-25. The study, led by the team...
HCW11‑018 T‑cell engager shows pancreatic activity
HCW Biologics reported preclinical antitumor activity for HCW11‑018, a T‑cell engager designed for pancreatic cancer (e18000a5cb072078). The company presented in vitro and in vivo data showing...
TEAD inhibitor VT‑3989 targets NF2‑deficient tumors
Vivace Therapeutics disclosed preclinical efficacy for VT‑3989, a TEAD inhibitor that suppressed aggressive NF2‑deficient tumor growth in vitro and in vivo (68e05edcb0400dd1). The company showed...
GD2 ADC M‑3554 posts potent antitumor effects
A new antibody‑drug conjugate, M‑3554, targeting GD2 showed robust antitumor activity in neuroblastoma and soft tissue sarcoma models (168c1410c7e7c25f). The ADC uses a β‑glucuronide cleavable...
Boehringer discloses cGAS inhibitors for inflammatory and fibrotic disease
Boehringer Ingelheim reported discovery of cyclic GMP‑AMP synthase (cGAS) inhibitors with potential across autoinflammatory and fibrotic indications (f0d08b4fdbedcc05). The company’s disclosure...
Lilly reports RXFP1 agonists for cardiorenal and kidney disease
Eli Lilly disclosed a series of RXFP1 (relaxin receptor 1) agonists described as candidates for pulmonary hypertension, kidney disease, and cardiorenal conditions (cdd0d021f719f7ee). The compounds...
Kymera patents STAT6 inhibitors for broad disease portfolio
Kymera Therapeutics revealed new patents on STAT6 inhibitors aimed at oncology, inflammation, fibrosis, and metabolic indications (d3aace0d1d6f498c). The disclosures describe small molecules...